Overview

Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Ipratropium
Criteria
Inclusion Criteria:

- Patients of both gender older than 40 years, who suffer from Chronic Obstructive
Pulmonary Disease

- Only patients who have not been treated with Atrovent® within the last year are to be
considered for inclusion

Exclusion Criteria:

- Contraindications listed in the Instructions for Use/Summary of Product
Characteristics for Atrovent® metered dose inhaler